Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Subscribe To Our Newsletter & Stay Updated